Amoxycillin 400 with Clavulanic Acid 57MG Dry Syrup Amoxycillin 400 with Clavulanic Acid 57MG Dry Syrup is an oral dry powder that is designed to deliver a specific dose of amoxycillin and clavulanic acid on reconstitution. The double strength formulation is thick and requires very careful powder disportionate, particle engineering, and effective controls on moisture and uniform suspension. This formulation can be added to a PCd Pharma Franchise product portfolio for pharma companies who offer a well managed PCD Pharma Franchise range backed by suitable manufacturing and packaing controls.
Dry Syrup Development Unlike conventional manufacturing of tablets or ready-to-use liquids, the final powder has to maintain its physical integrity upon storage and then form a defined suspension upon reconstitution. Formulation development thus involves the assessment of both the dry state characteristics and the final liquid suspension.
Preparation of a 400MG amoxycillin with 57MG clavulanic acid dry syrup: - After deciding the amount of concentration required to reconstitute, the formulation team sifts the active ingredients and the chosen excipient system so as to produce a powder that can be easily pressed out and dispersed properly after the addition of water.
Particle-size distribution, bulk density, and moisture behavior all can impact the final formulation performance. Excipient(s) may be used to provide flowability, wetability, dispersability, suspension stability, viscosity and other physical properties.
The increased active concentration also means that formulation uniformity becomes an important factor in development. The process of manufacture needs to guarantee the specified proportion of each active throughout a batch of product. As a result, raw-material identification and controlled dispensing are part of the manufacturing process.
Physicochemical properties of a dry powder can impact processability and ease of re-constitution. Variations in particle size or density between the active substances and excipients may result in powder mobility issues and potential segregation.
These properties can be modified or handled during the formulation process. These methods include controlled sieving, modification of particle size, pre-blending and other powder-conditioning procedures. The procedure used will be based on the nature of the ingredients and the quantity to be mixed.
Flow of the powder is more significant during bottle filling. A stable flow minimises the variations in weight for fills and can reduce product changes and pauses in continuous and semi-automated filling processes. Settings are selected based on the physical characteristics of the formulation and are monitored during manufacturing.
Sampling for Blend Uniformity Representative sampling can be performed to quantify the uniformity of the powder. Valid analytical methods have been used to verify that the potency has been evenly distributed prior to filling.
The reconstitution stage is a characteristic feature of the dry syrup product. Upon addition of the prescribed amount of water, the powder dispersed and generates a suspension of the physical characteristics defined at formulation development stage.
Wetting characteristics, the size of the particles and the material in suspension all affect how quickly the powder mixes into the solution. The finished product can be tested for reconstituting, ease of dispersability and redispersability after it has been allowed to stand.
Sedimentation properties. The settled volume or the rate of sedimentation should be predictable and redispersion of the sediment following appropriate settling conditions specified for the finished product. Viscosity can be examined during formulation optimization as it may impact the physical stability and ease of dispensing.
Both reconstituted volume and concentration are dependent on the accuracy of initial powder fill, and these aspects therefore are evaluated in conjunction during product development by means of fill-weight control and reconstitution testing.
Production control for this formulation begins when the components are dispensed and continues on to the final filling of bottles. The environment may be controlled in order to reduce any extraneous moisture exposure, given that a dry powder can have its physical characteristics changed with early moisture absorption.
During processing, parameters including blending time, powder transfer, filling speed and fill weight are monitored. In-Process inspection allows the detection of variations before the product is packed into the final container.
There may be tests for identification and assay of amoxycillin and clavulanic acid, as well as appropriate tests for powder uniformity, behaviour on reconstitution and finished-product quality. Analytical procedures should have adequate specificity for characterisation of the individual active components.
If relevant, physical description of the reconstituted suspension can be examined in accordance with the approved product specification. Complete batch records and analytical data shows traceability from raw materials received to release of final product.
The packaging system is an important aspect of dry syrups stability. The choice of pharmaceutical bottles, closures and the packaging they encapsulate is dependent on the moisture sensitivity of the formulation. The packaging is designed to protect the dry powder from handling and storage for the extent of its shelf life.
While developing packaging, considerations are given to container-closure integrity, fill volume, label position and product identification. Transparent packaging information aids in the straightforward handling of the product and batch identification.
Stability assessment investigates whether the dry formulation product keeps its specified physical and chemical attributes when stored under predefined conditions. The characteristics of reconstituted-product might be assessed as per the designated stability protocol.
Dedicated pharmaceutical entrepreneurs can add Amoxycillin 400 with Clavulanic Acid 57MG Dry Syrup in PCD Pharma Franchise Product Range, who want to establish a stronger and more varied pharma lineup. Regular formulation standards and manufacturing, appropriate moisture-proof packaging, and a documented quality analysis help to present your product in a more professional way.
Whole development of this dry syrup was due to make combination of concentration control, particle Engineering, powder flow control, suspension Engineering, dose filling &packaging characterization. All contribute to address the bottle-to-bottle reproducibility together with the difference qualities of finish formulation.
Amoxycillin 400mg with Clavulanic Acid 57mg Dry Syrup covering formulation design, suspension quality, manufacturing, stability and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech